Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Biofrontera (BFRI) over the last 4 years, with Q3 2025 value amounting to $3.0 million.

  • Biofrontera's Accumulated Expenses changed N/A to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year change of. This contributed to the annual value of $2.4 million for FY2024, which is N/A changed from last year.
  • Per Biofrontera's latest filing, its Accumulated Expenses stood at $3.0 million for Q3 2025.
  • In the past 5 years, Biofrontera's Accumulated Expenses registered a high of $5.6 million during Q1 2022, and its lowest value of $2.4 million during Q2 2025.
  • Moreover, its 4-year median value for Accumulated Expenses was $2.5 million (2022), whereas its average is $3.6 million.
  • Examining YoY changes over the last 5 years, Biofrontera's Accumulated Expenses showed a top increase of 5535.71% in 2023 and a maximum decrease of 5535.71% in 2023.
  • Quarter analysis of 4 years shows Biofrontera's Accumulated Expenses stood at $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then dropped by 2.88% to $2.4 million in 2024, then increased by 22.49% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $2.4 million for Q2 2025, and $2.5 million during Q1 2025.